We focus on the research needs of tumor diseases and have developed a series of new immunodeficient mice, rats, and humanized immune system reconstruction models, continuously promoting product iteration and upgrades to meet the demands for tumor models with new targets, new mechanisms, new therapies, more precision, and longer research windows. From the first domestically developed highly immunodeficient mouse NPG and radiation-resistant NRG to the earliest commercialized highly immunodeficient rat F344RG in China, and from basic human immune system reconstruction mice HuHSC-NPG and HuPBMC-NPG to the second-generation humanized mice NPG-GM3 and HuPBMC-DK-NPG with human cytokines to promote the development of immune cells or other gene modifications, and to the more accurate antibody drug evaluation mice NPG-FcgRs, we have achieved the vision of technological leadership and market cultivation in the field of humanized models in China after 24 years of relentless pursuit and continuous development.